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Edited by Richard MaraisAbstract The retinoic acid-induced diﬀerentiation of human
leukemia HL-60 cells towards mature granulocytic cells was
accompanied by the decline in the protein levels of c-myc, nucle-
ophosmin/B23 and its promoter activity. These RA-induced ef-
fects were further enhanced by the concurrent treatment of
HL-60 cells with p38 map kinase inhibitor SB203580 (SB). It
seems that there is a strong correlation of nucleophosmin/B23
and c-Myc expressions in cells under RA treatment. Further-
more, nucleophosmin/B23 promoter activity decreased upon
c-Myc antisense-mediated reduction of intracellular amount of
c-Myc. CHIP assays showed that binding of c-Myc to the nucle-
ophosmin/B23 promoter decreased in RA-treated cells. Thus,
nucleophosmin/B23 expression is targeted by c-Myc during
RA-induced diﬀerentiation. These results provide evidence for a
novel mechanism of transcriptional downregulation of nucleo-
phosmin/B23 and the functional role of c-Myc in RA-induced dif-
ferentiation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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One important diﬀerence between cancer and normal cells is
hyperactivity and pleomorphism of the nucleoli [1]. The
nucleolus in cancer cells undergoes extreme variations in size,
shape, ﬁne structure, and cytochemical composition [2].
Uncontrolled cell proliferation is the hallmark of cancer, and
tumor cells have typically acquired damage to genes that di-
rectly regulate their cell cycles and cell growth. Although
rRNA transcription, processing and ribosome assembly have
been established as major functions of nucleolus, previous
studies suggest that nucleolus participates in many other as-
pects of gene expression as well [3]. New results indicate that
biosyntheses of signal recognition particle RNA and telome-
rase RNA involve a nucleolar stage and that nucleolus is a site
critical to cellular aging [4]. A number of studies including ours
indicate that nucleophosmin/B23, one of the major nucleolar
phosphoproteins, plays a role in increased nucleolar activity
that is necessary for cell proliferation [5]. The steady-state level*Fax: +886 3 211 8615.
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doi:10.1016/j.febslet.2004.08.089of nucleophosmin/B23 mRNA is signiﬁcantly higher in abnor-
mal growth than in normal growth [6]. In the analysis of clin-
ical cancer tissues, cancers of later stages or recurrent cancers
seem to have higher nucleophosmin/B23 mRNA levels [7]. The
functional association of nucleophosmin/B23 with cancer sug-
gests that excess of nucleophosmin/B23 could be an important
cause of cancer and not just a consequence.
Several signaling pathways are activated by retinoic acid
(RA) to mediate induction of diﬀerentiation. ERK/MAPK
activation is needed to elicit RA-induced cellular diﬀerentia-
tion [8]. P38 MAP kinase pathway is activated and exhibits
negative regulatory eﬀects on RA-induced diﬀerentiation
[9]. Previously, we have found that nucleophosmin/B23 is
transcriptionally downregulated during RA-induced diﬀeren-
tiation [10]. Nucleophosmin/B23 antisense oligomer treat-
ment signiﬁcantly potentiates RA-induced diﬀerentiation.
Thus, nucleophosmin/B23 plays a role in control of cellular
susceptibility to RA. The biochemical and molecular events
involved in cellular response to RA include a modulation
of nucleophosmin/B23 gene expression. In this study, at-
tempts were therefore made to elucidate how nucleophos-
min/B23 was aﬀected by RA. Since the human
nucleophosmin/B23 locus contains c-Myc binding site [11].
Antisense-mediated reduction and chromatin immunoprecip-
itation (CHIP) were carried out to determine whether
c-Myc indeed binds and regulates nucleophosmin/B23 pro-
moter during RA-induced diﬀerentiation. Our results show
that the cellular protein levels of c-Myc and nucleophos-
min/B23 decrease during RA-induced diﬀerentiation. Nucleo-
phosmin/B23 promoter activity decreases upon RA treatment
and upon antisense-mediated reduction of the intracellular
amount of c-Myc. Moreover, the binding of c-Myc to nucle-
ophosmin/B23 promoter decreases upon RA treatment.
Our results functionally implicate c-Myc in transcriptional
regulation of nucleophosmin/B23 during RA-induced
diﬀerentiation.2. Materials and methods
2.1. Cell culture and antibody
HL-60 leukemic cells were grown in suspension in RPMI-1640 med-
ium supplemented with 10% heat-inactivated fetal bovine serum, 0.5%
antibiotics and 2.0 g/l sodium bicarbonate in a 5% CO2 humidiﬁed
incubator at 37 C. The monoclonal antibody (MAb) to nucleophos-
min/B23 (37/5.1) was kindly provided by Dr. P.K. Chan, Department
of Pharmacology, Baylor College of Medicine, Houston, Texas. Char-
acterization of nucleophosmin/B23 MAb has been reported previously
[12].blished by Elsevier B.V. All rights reserved.
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The phosphorothioate analogs of deoxyoligonucleotides corre-
sponding to nucleotides 2 to 18 of the c-myc cDNA were synthesized
in both of the reverse (5 0-GCT ACG GGG AGT TGC AAT CG-3 0)
and antisense (5 0-GCT AAC GTT GAG GGG CAT CG-3 0) orienta-
tions (ASIA Company Ltd., Oregon-Wilsonville).
2.3. Induction of diﬀerentiation
For the induction of diﬀerentiation, HL-60 cells (2 · 105 cells/ml)
were incubated with 1 or 5 lM RA (all-trans). The percentages of
CD-11b-positive cells and ﬂuorescence intensity were evaluated by
FACScan (FACScan, Beckton-Dickinson) using speciﬁc anti-CD11b
FITC-conjugated MAb (Sigma).
2.4. Western blotting
Separated proteins on SDS–PAGE were electrotransferred to Hy-
bond-PVDF membrane (Amersham Pharmacia Biotech, Uppsala,
Sweden). The PVDF membrane was then soaked in a blocking solu-
tion [5% (w/v) non-fat milk in TBST buﬀer (20 mM Tris–HCl, pH
7.5, 0.5 M NaCl, and 0.1% (v/v) Tween 20)] for 1 h at room tempera-
ture. The soaked PVDF membrane was then incubated with MAb
against nucleophosmin/B23 (diluted 1:2000 in 3% (w/v) non-fat milk
in TBST) for 1 h at room temperature, washed with TBST buﬀer three
times for 15 min each and incubated at room temperature for 1 h in
horseradish peroxidase conjugated goat anti-mouse IgG antibody (di-
luted 1:2000 in TBST buﬀer). The membrane was washed three times
with TBST for 15 min each. Immunobands were identiﬁed by en-
hanced chemiluminescence reaction (ECL, Amersham Pharmacia Bio-
tech).
2.5. Transfection with antisense c-Myc oligonucleotides
HL-60 cells were seeded at a density of 3 · 105 per well in 1.0 ml
OPTI-MEM I reduced serum medium (Gibco). One to 5 micromolar
oligonucleotide (c-Myc reverse or antisense) and 6 lg lipofectin re-
agents in OPTI-MEM I reduced serum medium were mixed gently.
The mixture was incubated for 45 min at room temperature, added
to the HL-60 cells and was incubated for 24 h at 37 C in the CO2 incu-
bator.
2.6. Plasmid
The 5 0 region of nucleophosmin/B23 gene (552/+2217) containing
c-Myc binding site was cloned into luciferase reporter gene vector
pGL3 vector. Genome nucleophosmin/B23 was ampliﬁed by PCR
using 5 0-CGA GGT ACC TGA ACT TTG GGG TAA-3 0 and 5 0-
TAG TCC ATG GGC CTT TAG TTC ACA ACC-3 0 as primers.
Ampliﬁed PCR products were then separated and isolated from 1%
agarose gel. The 2.7 kb nucleophosmin/B23 genome region was then
subcloned into the cloning site of the vector pGL3 supplied in the
Eukaryotic TA cloning kit. The orientation of the cDNA in pGL3
was determined by nucleotide sequencing using the sequence kit
(Amersham Pharmacia Biotech).Fig. 1. Eﬀect of RA on the levels of nucleophosmin/B23 and c-Myc proteins.
h. The cells were then treated with 1 or 5 lM RA for 24–96 h (A) or with 1
washed and the lysates were centrifuged at 12000 · g for 30 min at 4 C. 3
blotted onto PVDF papers. Nucleophosmin/B23 (B23), c-Myc and b-actin w
ECL reaction.2.7. Transient transfection by electroporation
5 · 107cells were washed twice with ice-cold PBS, resuspended in 0.3
ml PBS and then transferred to electrochamber containing 40 lg of re-
porter plasmid. Electroporation was performed using the GIBCO-
BRL gene pulser with a capacitance setting of 1180 lF and a voltage
setting of 260 V. After electroporation, cells were incubated on ice
for 10 min and transferred to 35 ml fresh RPMI 1640 medium contain-
ing 10% FBS. After 24 h, cells were then treated with RA for various
times.
2.8. Luciferase and b-galactosidase activity assays
The cells were washed with PBS twice and lysed in Reporter Lysis
Buﬀer (Promega, Madison, WI) after transfection. 40 ll of cell lysate
was automatically mixed with the luciferase assay substrate (Promega,
Madison, WI). Luciferase activity was quantiﬁed in a luminomer
AutoLunmat LB953 (Berthold, Norwalk, CT). For b-galactosidase
activity assay, 40 ll of cell lysate was mixed with the reaction buﬀer
[200 mM sodium phosphate buﬀer (pH 7.3), 2 mM MgCl2, 100 mM
b-mercaptoethanol, and 1.33 mg/ml ONPG (o-nitrophenyl-b-D-galac-
topyranoside)] and was incubated at 37 C for 30 min. 500 ll of
Na2CO3 was added to the reaction mixture and the optical density
at a wavelength of 420 nm was recorded. Luciferase activity was nor-
malized to the b-galactosidase activity of the same sample.
2.9. Chromatin immunoprecipitation
Cells were cross-linked by adding formaldehyde (ﬁnal concentration,
1%) directly to the cells in a culture ﬂask for 20 min at 37 C. Cells were
collected by centrifugation and washed with ice cold PBS. Cells were
lysed in SDS lysis buﬀer (Upstate, Lake Placid, NY) [1% SDS, 10
mM EDTA, 50 mM Tris–HCl (pH 8.1), and 1 mM phenylmethylsul-
fonyl ﬂuoride] and incubated on ice for 20 min. Samples were then son-
icated on ice and then centrifuged at 14 000 rpm. The chromatin
solution was precleared with Salmon Sperm DNA/Protein A Agarose
– 50% Slurry for 30 min at 4 C with agitation. Precleared supernatant
from 2.5 · 107 cells was incubated with 4 lg of rabbit polyclonal anti-
body (Santa Cruz: anti-Myc sc-764), or with no antibody and rotated
at 4 C for 12 h. Immunoprecipitation, washing, and elution of im-
mune complexes with 1% SDS and 0.1 M NaHCO3 were carried
out. Crosslinks were reversed by addition of NaCl to a ﬁnal concentra-
tion of 200 mM and RNA was removed by addition of 10 lg of RNase
A per sample followed by incubation at 65 C for 5 h. 10 ll of 0.5 mM
EDTA, 20 ll of 1 M Tris–HCl, pH 6.5, and 2 ll of 10 mg/ml Proteinase
K to the eluates (500 ll) and the samples were incubated at 45 C for 1
h. Samples were extracted with phenol:chloroform:isoamyl alcohol
(25:24:1) and resuspended in 20 ll of H2O, and analyzed by using
PCR. Total input samples were resuspended in 100 ll of H2O before
PCR. PCRs contained 1 ll of immunoprecipitate, 50 ng of each pri-
mer, 0.88 mM MgCl2, 2 mM each of dATP, dCTP, dGTP, dTTP,
and 1X Thermophilic buﬀer (Promega), and 1.25 units TaqDNA poly-
merase (Promega) in a total volume of 25 ll. After 32–35 cycles of
ampliﬁcation, PCR products were run on a 2.5% agarose gel and ana-
lyzed by ethidium bromide staining.HL-60 cells were pretreated without or with 20 lM SB203580 (SB) for 1
or 5 lM for 4–24 h (B). Cells were then harvested at indicated times,
0 lg of total cellular proteins was separated by 10% SDS–PAGE and
ere detected by Western blot using respective speciﬁc antibodies and
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3.1. Eﬀect of RA on the levels of nucleophosmin/B23 and c-Myc
proteins
Total cellular lysates (containing equal amounts of protein)
from control untreated HL-60 cells or the HL-60 cells treated
with 1 or 5 lM RA for various times (24–96 h, 4–24 h) were
separated by 10% SDS–PAGE and subsequently analyzed by
Western blot immunoassay. The results showed that there
was a decrease in the level of total cellular nucleophosmin/
B23 protein during RA-induced diﬀerentiation (Fig. 1A). After
72 h of 5 lM RA treatment, nucleophosmin/B23 protein level
decreased to about 20%. Co-treatment of HL-60 cells with p38
map kinase inhibitor SB203580 (SB) enhanced the RA-induced
diﬀerentiation (Fig. 2), and the decrease of nucleophosmin/B23
(Fig. 1A) and c-Myc proteins (Fig. 1B). Culturing the cells for
72 h with 5 lMRA caused a marked increase in diﬀerentiation
marker, CD11b. In addition, there was signiﬁcantly elevated
CD11b expression in cells treated with SB and RA as com-
pared to the cells treated with RA alone (Fig. 2). Nucleophos-
min/B23 protein level in SB co-treated cells further decreased
to less than 10% after 72 h of 5 lM RA treatment (Fig. 1A).
In parallel, c-Myc protein level changed in similar manner dur-
ing RA-induced diﬀerentiation. The reduction of c-Myc oc-
curred in larger extent and within shorter times (4–24 h)
during RA-induced diﬀerentiation in the presence of SB (Fig.
1B) as compared with RA treatment alone without SB.Fig. 2. SB potentiated RA-induced diﬀerentiation as measured by the
expression of diﬀerentiation marker. HL-60 cells were pretreated
without or with 20 lM SB203580 (SB) for 1 h. The cells were then
treated with 5 lM RA for 72 h. After the cells were harvested,
expressions of the CD11b were evaluated by cytoﬂuorimetry using
speciﬁc anti-CD11b FITC-conjugated MAb. The ﬁgure is a represen-
tative of the results obtained from at least three independent
experiments.3.2. Downregulation of nucleophosmin/B23 promoter by RA
To further determine the eﬀect of RA on nucleophosmin/B23
gene expression, we tested the responsiveness of nucleophos-
min/B23 promoter-reporter construct (pGL3-B23I1) to RA
treatment. Fig. 3A shows the schematic diagram of nucleo-
phosmin/B23 promoter and its c-myc binding sites (11). Nucle-
ophosmin/B23 promoter activity was decreased after RA
treatment (1–5 lM, 24 h) (Fig. 3B). There was about 22 ± 5%
and 48 ± 3% decrease of nucleophosmin/B23 promoter activity
in HL-60 cells at 12 h after 1 and 5 lM RA treatment, respec-
tively (Fig. 3B). Co-treatment of HL-60 cells with SB potenti-
ated RA-induced downregulation of nucleophosmin/B23
promoter. About 50.0 ± 2% decrease of nucleophosmin/B23
promoter activity was observed in HL-60 cells treated with 1
lM RA in the presence of 10 lM SB (Fig. 3B). We have also
performed the promoter activity analysis for 48 and 72 h of
RA treatment. There was still only about 50% decrease of
nucleophosmin/B23 promoter activity in HL-60 cells at 48 or
72 h after 5 lM RA treatment (Fig. 3C). In the reporter assay
with construct having deletion of intron 1 sequences (744/
+97) where the c-myc-binding sites are located, virtually no
reduction of nucleophosmin/B23 promoter activity was ob-
served during RA treatment (1–5 lM, 24 h) (Fig. 3D).3.3. c-Myc regulates nucleophosmin/B23 promoter activity
Since there was a strong correlation of nucleophosmin/B23
and c-Myc expressions in cells upon RA treatment, we next
sought to determine whether expression of nucleophosmin/
B23 was targeted by c-Myc during RA-induced diﬀerentiation.
We ﬁrst analyzed the changes of nucleophosmin/B23 promoter
activity upon antisense-mediated reduction of the intracellular
amount of c-Myc. Western blot analysis (Fig. 4A) showed that
there were decreases in protein levels of c-Myc in the cells trea-ted with c-Myc antisense oligomer as compared to the control
untreated cells. In addition, c-Myc antisense oligomer treat-
ment signiﬁcantly deactivated nucleophosmin/B23 promoter
(Fig. 4B). There was virtually no eﬀect of c-Myc reverse oligo-
mer treatment on the nucleophosmin/B23 promoter activity
(Fig. 4B). Next, we examined whether c-Myc bound and di-
rectly regulated nucleophosmin/B23 gene during RA-induced
diﬀerentiation. Chromatin was collected after RA treatment
(5 lM, 24 h) and CHIP analysis was performed using an anti-
body against c-Myc (Fig. 4C). Our results demonstrated that
c-Myc binding to the nucleophosmin/B23 promoter site was
Fig. 3. Eﬀect of RA on nucleophosmin/B23 promoter activity. (A) The schematic diagram of nucleophosmin/B23 promoter containing the c-myc
binding site. (B) HL-60 cells were transiently co-transfected with nucleophosmin/B23 promoter plasmid (pGL3-b23I1) and SV40-b-galactosidase (as
an internal control). Twenty-four hours after transfection, cells were subcultured and then were pre-treated with or without 10 lM SB203580 (SB) for
1 h. Cells were then treated with 1 or 5 lM RA for 12 h before being harvested and lysed by reporter lysis buﬀer. The cell extracts containing equal
amounts of proteins were analyzed for luciferase activity and b-galactosidase activities. Luciferase activity was normalized to the b-galactosidase
activity of the same sample. Fold activation was determined by dividing the luciferase activity of each sample by basal luciferase activity of control
without any drug treatment. Bars represent means of triplicates ± S.D. *P < 0.05, as compared with nucleophosmin/B23 promoter activity in control
cells. (C) HL-cells were treated with 5 lM RA for 48 and 72 h before promoter activity was analyzed. *P < 0.05, as compared with nucleophosmin/
B23 promoter activity in control cells. (D) The reporter assay was carried out with construct having deletion of intron 1 sequences (744/+97) where
the c-myc-binding sites are located. HL-cells were treated with 5 lM RA for 12 h before promoter activity was analyzed.
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trol untreated cells (Fig. 4C).4. Discussion
Nucleophosmin/B23 is enriched in proliferating cells and
thought to be involved in ribosome assembly and transport
due to its localization to the granular region of the nucleolus
[12]. Nucleophosmin/B23 has been ascribed a number of di-
verse properties, including a potential role in proliferation
due to its rapid increase in synthesis during mitogenic stimula-
tion [13]; a role as a cytoplasmic/nuclear shuttle protein [14];
relieves transcription repression by YY1 [15]; binds the HIV
Type 1 Rev protein [16], the human T-cell leukemia virus-1-
Rex protein [17], and another cell cycle-regulated nucleolar
oncoprotein p120 [18]; is a substrate of protein kinase C [19],mitotic cdc2 kinase [20], and casein kinase II [21]; and can
be ADP-ribosylated [22]. Nucleophosmin/B23 is of potential
interest because it is involved in at least three distinct forms
of hematologic malignancy. The N-terminal region of nucleo-
phosmin/B23 is fused to ALK tyrosine kinase in anaplastic
lymphoma with t(2;5) [23], to RA receptor a in acute promye-
locytic leukemia with t(5;17) [24], and to a novel gene called
MLF1 in myelodyplastic syndrome with t(3;5) [25].
In light of many potential roles of nucleophosmin/B23, it is
conceivable that it plays important role in the regulation of cell
growth. In our previous studies, HL-60 cultures induced to dif-
ferentiate with RA are shown to contain markedly reduced lev-
els of nucleophosmin/B23 mRNA when compared with
control HL-60 cells. The nucleophosmin/B23 protein levels,
on the other hand, persist after 24 h of negligible transcript
[10]. Nucleophosmin/B23 has a protein half-life of 18–20 h
[26]. The stabilities of the nucleophosmin/B23 transcripts of
Fig. 4. c-Myc binding and transcriptional activation of nucleophos-
min/B23 promoter decreased during RA-induced diﬀerentiation. (A, B)
Eﬀect of c-Myc antisense oligonucleotide on nucleophosmin/B23
promoter activity. HL-60 cells were transiently co-transfected with
nucleophosmin/B23 promoter plasmid (pGL3-b23I1) and SV40-b-
galactosidase (as an internal control). Six hours after transfection, cells
were subcultured and were treated without (control, C), or with 1, 2 or
5 lM c-Myc antisense oligomer (AS) for 24 h. Cells were then
harvested for Western blot (A). (B) Cells were treated with 1, 2 or 5 lM
c-Myc antisense oligomer (AS) or c-myc reverse oligomer for 24 h
before luciferase activity was measured and normalized to the b-
galactosidase activity of the same sample (B). Fold activation was
determined and represented as in Fig. 3. *P < 0.05, as compared with
nucleophosmin/B23 promoter activity in control cells. (C) eﬀect of RA
on c-Myc binding to nucleophosmin/B23 promoter. HL-60 cells were
treated with 5 lM RA for 24 h. Cells were then harvested, chromatin
was collected and CHIP analysis was performed using antibody
against c-Myc (C). The ﬁgure is a representative of the results obtained
from at least three independent experiments.
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the relative rates of synthesis of nucleophosmin/B23 gene indi-
cate that, subsequent to diﬀerentiation, a decrease in nucleo-
phosmin/B23-speciﬁc transcription occurs. These studies
demonstrate that transcriptional regulation is a major compo-
nent of the control of the nucleophosmin/B23 gene during dif-
ferentiation. Recently, we have shown that nucleophosmin/
B23 can be rapidly induced in response to UV [27]. The imme-
diate-early induction of nucleophosmin/B23 indicates the exis-
tence of a new regulatory pathway that might enable cells to
react rapidly upon induction of DNA damage. This is an
important evidence for the involvement of nucleophosmin/
B23 in an acute response of mammalian cells to environmental
stress.
Previous studies have shown that expression of c-Myc corre-
lates with nucleophosmin/B23 expression [28–31]. Wild-type
Rat1 ﬁbroblasts maintain a nucleophosmin/B23 transcript le-
vel 3.5-fold higher than ﬁbroblasts bearing deletion of myc
[28]. In myc-overexpressing avian bursal neoplasia, nucleo-phosmin/B23 transcript levels are 3.5-fold higher than in nor-
mal bursa [29]. Adenoviral transfection of c-Myc into mice
leads to dramatic increase in liver nucleophosmin/B23 mRNA,
which correlates with increasing myc protein levels 3–5 days
post-infection [30]. These studies indicate that increased myc
expression results in elevated nucleophosmin/B23 transcript le-
vel. Furthermore, myc binding site has been identiﬁed and ser-
um stimulation of nucleophosmin/B23 expression is shown to
be myc-dependent [11]. C-myc binds nucleophosmin/B23 pro-
moter in vivo and in vitro. C-myc could activate transcription
of nucleophosmin/B23 promoter [11]. In our present study,
CHIP was utilized to demonstrate the eﬀect of RA on binding
of c-Myc to nucleophosmin/B23 promoter, thus providing evi-
dence that c-Myc directly regulates nucleophosmin/B23 tran-
scription in cellular diﬀerentiation. Downregulation of
nucleophosmin/B23 transcription during RA-induced diﬀeren-
tiation is a consequence of the decrease of c-Myc binding to
the nucleophosmin/B23 promoter.
Interferon factor 1 (IRF-1) suppresses tumorigenicity of cells
transformed by c-Myc [32]. IRF-1 plays a role in cell growth
control and surveillance against cancer development [33].
Nucleophosmin/B23 interferes with IRF-1 binding to target
DNA sequences and attenuates the in vitro transcriptional
activity of IRF-1 [34]. Furthermore, the IRF-1 transcriptional
activity is attenuated in nucleophosmin/B23 overexpressed
cells. Thus, nucleophosmin/B23 through interacting with
IRF-1 plays an important role in the control of the susceptibil-
ity of cells to RA-induced diﬀerentiation [35]. We thus specu-
late that decrease of c-Myc binding to nucleophosmin/B23
promoter leads to downregulated expression of nucleophos-
min/B23. Without interference by nucleophosmin/B23, IRF-1
would then be free to transcriptionally activate the genes for
diﬀerentiation.
In conclusion, we have elucidated the mechanism for the
control of nucleophosmin/B23 expression. c-Myc is one of
the factors that binds and regulates nucleophosmin/B23 pro-
moter. The binding of c-Myc to nucleophosmin/B23 promoter
decreases in RA-induced diﬀerentiation. These results provide
the novel mechanism for transcriptional downregulation of
nucleophosmin/B23 and the functional role of c-myc during
RA-induced diﬀerentiation.
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